株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ロタウイルス感染症:パイプライン製品の分析

Rotavirus Infections - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 251575
出版日 ページ情報 英文 62 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
ロタウイルス感染症:パイプライン製品の分析 Rotavirus Infections - Pipeline Review, H2 2016
出版日: 2016年10月26日 ページ情報: 英文 62 Pages
概要

ロタウイルスは、腸を汚染するウイルスで、幼児と子供に見られるひどい下痢の最も一般的な原因です。ロタウイルスは、多くの場合糞口経路を経て感染します。通常、これは手洗が不十分だったり、汚染食品や水を摂取することから起こります。ウイルスは気道を通して、または、他の体液によって伝播もすることもありますが、それほど多くありません。ウイルスは、無生物表面(例えばドアノブ、おもちゃや硬表面)にいることもあります。 症状としては、ひどい下痢、嘔吐、熱や脱水症などがみられます。

当レポートでは、ロタウイルス感染症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

ロタウイルス感染症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

ロタウイルス感染症:企業で開発中の治療薬

ロタウイルス感染症:大学/機関で研究中の治療薬

ロタウイルス感染症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

ロタウイルス感染症:企業で開発中の製品

ロタウイルス感染症:大学/機関で研究中の製品

ロタウイルス感染症の治療薬開発に従事している企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Biological E. Limited
  • CureVac GmbH
  • Medicago Inc.
  • Nanotherapeutics, Inc.
  • SEEK Group
  • Serum Institute of India Limited
  • Shantha Biotechnics Limited
  • Sinovac Biotech Ltd.

武田薬品工業

ロタウイルス感染症:治療薬の評価

  • 単剤製品
  • 標的別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

ロタウイルス感染症:最近のパイプライン動向

ロタウイルス感染症:休止中のプロジェクト

ロタウイルス感染症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8573IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Pipeline Review, H2 2016, provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape.

Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs through fecal-oral contact. Usually, this occurs from poor hand washing or from ingestion of contaminated food or water. The virus may also be transmitted through the respiratory tract or by other body fluids, but these routes are less common. The virus may live on inanimate surfaces, such as doorknobs, toys, and hard surfaces. Symptoms may include severe diarrhea, vomiting, fever, and dehydration.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rotavirus Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rotavirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rotavirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 1, 6 and 2 respectively for Similarly, the Universities portfolio in Phase II and Discovery stages comprises 4 and 1 molecules, respectively for Rotavirus Infections.

Rotavirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rotavirus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rotavirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rotavirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rotavirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rotavirus Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rotavirus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rotavirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rotavirus Infections Overview
  • Therapeutics Development
    • Pipeline Products for Rotavirus Infections - Overview
    • Pipeline Products for Rotavirus Infections - Comparative Analysis
  • Rotavirus Infections - Therapeutics under Development by Companies
  • Rotavirus Infections - Therapeutics under Investigation by Universities/Institutes
  • Rotavirus Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Rotavirus Infections - Products under Development by Companies
  • Rotavirus Infections - Products under Investigation by Universities/Institutes
  • Rotavirus Infections - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • Bharat Biotech International Limited
    • Biological E. Limited
    • Curevac AG
    • Medicago Inc.
    • MSD Wellcome Trust Hilleman Laboratories Pvt Ltd
    • Nanotherapeutics, Inc.
    • Serum Institute of India Limited
    • Shantha Biotechnics Limited
    • Sinovac Biotech Ltd.
    • Takeda Pharmaceutical Company Limited
    • Wuhan Institute of Biological Products Co., Ltd.
  • Rotavirus Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Rotavac-5C - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rotavirus (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus [Serotype P2-VP8] (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus [Serotype P2] (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rotavirus [serotypes G1, G2, G3, G4, P1] (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rotavirus [serotypes G1, G2, G3, G4] (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RV-3BB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RV-625 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rotavirus Infections - Dormant Projects
  • Rotavirus Infections - Product Development Milestones
    • Featured News & Press Releases
      • Sep 21, 2016: Batavia Biosciences receives grant to develop new vaccine against rotavirus
      • Oct 14, 2014: Shantha`s Investigational Rotavirus Vaccine Enters Phase III Clinical Trials in India
      • Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate
      • Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus
      • Apr 26, 2012: GSK's Rotarix to Be Introduced in Ghana
      • Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan
      • May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Rotavirus Infections, H2 2016
  • Number of Products under Development for Rotavirus Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Rotavirus Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
  • Rotavirus Infections - Pipeline by Bharat Biotech International Limited, H2 2016
  • Rotavirus Infections - Pipeline by Biological E. Limited, H2 2016
  • Rotavirus Infections - Pipeline by Curevac AG, H2 2016
  • Rotavirus Infections - Pipeline by Medicago Inc., H2 2016
  • Rotavirus Infections - Pipeline by MSD Wellcome Trust Hilleman Laboratories Pvt Ltd, H2 2016
  • Rotavirus Infections - Pipeline by Nanotherapeutics, Inc., H2 2016
  • Rotavirus Infections - Pipeline by Serum Institute of India Limited, H2 2016
  • Rotavirus Infections - Pipeline by Shantha Biotechnics Limited, H2 2016
  • Rotavirus Infections - Pipeline by Sinovac Biotech Ltd., H2 2016
  • Rotavirus Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Rotavirus Infections - Pipeline by Wuhan Institute of Biological Products Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Rotavirus Infections - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Rotavirus Infections, H2 2016
  • Number of Products under Development for Rotavirus Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top